Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adaptimmune Therapeutics (ADAP – Research Report), Ionis Pharmaceuticals (IONS – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report).
Adaptimmune Therapeutics (ADAP)
In a report issued on May 15, Jonathan Chang from Leerink Partners maintained a Hold rating on Adaptimmune Therapeutics, with a price target of $2.00. The company’s shares closed last Friday at $1.11.
According to TipRanks.com, Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptimmune Therapeutics with a $2.20 average price target, implying an 89.7% upside from current levels. In a report issued on May 15, Wells Fargo also maintained a Hold rating on the stock with a $2.00 price target.
See the top stocks recommended by analysts >>
Ionis Pharmaceuticals (IONS)
In a report issued on May 16, Mani Foroohar from Leerink Partners maintained a Hold rating on Ionis Pharmaceuticals. The company’s shares closed last Friday at $37.31, close to its 52-week low of $35.44.
According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Ionis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $58.93, implying a 56.9% upside from current levels. In a report issued on May 16, J.P. Morgan also maintained a Hold rating on the stock.
Ultragenyx Pharmaceutical (RARE)
In a report issued on May 16, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Ultragenyx Pharmaceutical. The company’s shares closed last Friday at $41.87.
According to TipRanks.com, Schwartz is a 2-star analyst with an average return of
Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $92.15, which is an 115.8% upside from current levels. In a report issued on May 2, Wells Fargo also maintained a Buy rating on the stock with a $72.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADAP:
